Michael Weichenthal

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 148 publications

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Journal: Cancers

Published: January 13, 2026

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 10, 2025

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Journal: The British journal of dermatology

Published: August 06, 2025

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 03, 2025

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis.

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: July 31, 2025

Bexarotene signaling in human B and T lymphocytes induces gut-homing receptor expression.

Bexarotene signaling in human B and T lymphocytes induces gut-homing receptor expression.

Journal: Frontiers in immunology

Published: July 11, 2025

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Journal: International journal of cancer

Published: May 23, 2025

Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG.

Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 18, 2025

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 24, 2025

Showing 1-12 of 148

Last Updated: 09/26/2026